Prot #TAK01796: Characterization of Early Response to Vedolizumab and IL-23 Antagonists in Participants with Crohn’s Disease Using Patient-Reported Outcome Measures (VOICE): A Prospective Observational Study

Project: Research project

Project Details

StatusActive
Effective start/end date3/20/25 → 3/20/28

Funding

  • Robarts Clinical Trials Inc (Prot #TAK01796 // Prot #TAK01796)
  • Takeda Development Center Americas, Inc. (Prot #TAK01796 // Prot #TAK01796)